Zhejiang East Asia Pharmaceutical Co. Ltd.

Zhejiang East Asia Pharmaceutical Co. Ltd.

605177 · SHG · Healthcare / Biotechnology

18.55CNY-0.94 (-4.82%)

Price History

Full chart

Market Stats

Previous Close19.49
Open19.75
Day Range18.00 – 19.75
52-Week Range13.71 – 26.58
Volume5.60M
Market Cap2.78B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.49
Dividend Yield0.00%
Beta0.85
50-Day Avg21.01
200-Day Avg20.49

About

Zhejiang East Asia Pharmaceutical Co., Ltd., together with its subsidiaries, produces and sells pharmaceutical chemicals, tablets, granules, intermediates, and capsules in China and internationally. It offers quinolones synthetic antibacterial agents, antifungal products, gastrointestinal medications, semi-synthetic cephalosporin antibiotics, carbapenem antibiotics, antiviral agents, central nervous system medications, respiratory drugs, antiallergic agents, antineoplastic agents and tumor adjuvant drugs, and other products. The company's products are used in cardiovascular, anti-aging, dementia, digestive system, diabetic neuropathy, anti-pathogenic microorganisms, infection, and central nervous system fields. It exports its products. The company was founded in 1998 and is headquartered in Taizhou, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Cheng Chi
  • Employees1.51K
  • HeadquartersChamber of Commerce Building, Taizhou, China, 318020, China
  • Websitehttps://www.eapharm.cn

Leadership

  • Mr. Cheng ChiGM & Chairman · b. 1984
  • Ms. Xiaomin WangFinancial Manager · b. 1971
  • Mr. Daomin XiaDeputy GM & Director · b. 1963

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue684.47M728.89M856.81M988.09M881.67M712.22M1.18B1.36B1.20B940.19M
Growth (%)-+6.49%+17.55%+15.32%-10.77%-19.22%+65.62%+15.00%-11.66%-21.54%
Cost of Revenue471.09M510.10M581.71M653.17M588.04M521.62M913.49M1.01B1.00B718.12M
Gross Profit213.38M218.79M275.10M334.92M293.63M190.60M266.06M348.75M194.21M222.07M
Gross Margin31.17%30.02%32.11%33.90%33.30%26.76%22.56%25.71%16.21%23.62%
Operating Expense133.95M150.81M142.15M137.77M159.86M111.67M145.47M211.78M295.94M252.60M
Operating Income79.43M67.98M132.95M197.15M133.77M78.92M120.59M136.97M-101.73M-30.53M
Operating Margin11.61%9.33%15.52%19.95%15.17%11.08%10.22%10.10%-8.49%-3.25%
EBITDA151.18M142.24M193.18M258.03M194.31M146.46M208.09M247.22M16.24M84.10M
EBITDA Margin22.09%19.52%22.55%26.11%22.04%20.56%17.64%18.23%1.36%8.94%
Net Income66.75M55.74M109.34M168.33M114.48M68.49M104.43M121.25M-100.66M-82.39M
Net Income Margin9.75%7.65%12.76%17.04%12.98%9.62%8.85%8.94%-8.40%-8.76%
R&D27.01M31.05M32.70M37.19M38.41M37.29M44.95M81.74M117.02M86.76M
R&D as % of Total Revenue3.95%4.26%3.82%3.76%4.36%5.24%3.81%6.03%9.77%9.23%
Interest Expense18.02M16.90M7.53M3.34M1.14M763.68K1.31M4.12M2.81M17.35M
Interest Expense % of Total Revenue2.63%2.32%0.88%0.34%0.13%0.11%0.11%0.30%0.23%1.85%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.03B1.17B1.09B1.11B2.08B2.25B2.47B3.34B3.56B3.34B
Total Liabilities599.74M533.63M382.88M258.55M351.79M492.99M631.57M1.33B1.68B1.53B
Total Equity426.33M632.13M710.90M848.04M1.73B1.76B1.84B2.02B1.87B1.81B
Cash73.18M189.47M111.97M133.23M989.38M556.10M501.58M711.12M513.18M243.97M
Total Debt330.00M279.00M98.50M20.00M10.01M2.38M122.76M706.93M780.98M-
Net Debt256.82M89.53M-13.47M-113.23M-979.37M-553.72M-378.82M-4.20M267.80M736.98M

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow54.35M91.66M143.64M216.63M146.90M-23.60M-70.35M-84.06M-156.55M-268.86M
Investing Cash Flow-38.53M-27.53M-28.62M-57.00M-50.57M-334.20M-63.98M-335.27M-90.16M-
Financing Cash Flow-39.94M70.31M-189.29M-138.38M744.46M-54.12M88.48M617.02M31.54M-
Capital Expenditure40.11M28.18M29.47M57.78M61.08M121.97M87.82M227.47M211.61M74.26M
Free Cash Flow14.24M63.48M114.17M158.84M85.82M-145.57M-158.17M-311.53M-368.16M-343.11M
Dividends Paid17.09M17.09M8.01M64.88M15.34M39.76M22.72M36.25M41.60M8.61M
FCF to OCF26.19%69.26%79.48%73.33%58.42%616.85%224.83%370.60%235.17%127.62%
Dividend Paid to FCF120.06%26.93%7.02%40.84%17.87%-27.31%-14.36%-11.64%-11.30%-2.51%

Earnings

Report DateDec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023
EPS Estimate-----------
EPS Actual0.060.220.30-0.040.130.200.170.170.380.200.28
Surprise-----------
Timing-----------

Key Statistics & Ratios

Market Cap2.78B
Enterprise Value3.46B
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.81
Price / Book1.68
EPS-1.49
Book Value14.65
Revenue (TTM)990.47M
Gross Profit (TTM)122.22M
EBITDA2.80M
Profit Margin-17.22%
Operating Margin-49.11%
Return on Equity-9.59%
Return on Assets-3.20%
Shares Outstanding114.71M
Shares Float54.53M
Beta0.85
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20241×
0.33Jul 4, 2024
20231×
0.29Jun 15, 2023
20221×
0.20Jun 8, 2022
20211×
0.35Jun 25, 2021